

Edvan De Queiroz Crusoe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6510717/publications.pdf>

Version: 2024-02-01

49
papers

1,035
citations

759055

12
h-index

454834

30
g-index

49
all docs

49
docs citations

49
times ranked

1277
citing authors

#	ARTICLE	IF	CITATIONS
1	POEMS Syndrome: Real World Experience in Diagnosis and Systemic Therapy - 108 Patients Multicenter Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 297-304.	0.2	11
2	Monoclonal gammopathy of renal significance (MGRS): Real world data on outcomes and prognostic factors. <i>American Journal of Hematology</i> , 2022, 97, 877-884.	2.0	12
3	Results of the daratumumab monotherapy early access treatment protocol in patients from Brazil with relapsed or refractory multiple myeloma. <i>Hematology, Transfusion and Cell Therapy</i> , 2021, 43, 417-423.	0.1	2
4	Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. <i>Lancet, The</i> , 2021, 397, 2361-2371.	6.3	177
5	Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. <i>New England Journal of Medicine</i> , 2021, 385, 46-58.	13.9	268
6	Evaluation of Hematopoietic Stem Cell Product As a New Site for Minimal Residual Disease By Next Generation Flow in Multiple Myeloma. <i>Blood</i> , 2021, 138, 4927-4927.	0.6	0
7	COVID-19 in Multiple Myeloma Patients: Frequencies and Risk Factors for Hospitalization, Ventilatory Support, Intensive Care Admission and Mortality -Cooperative Registry from Grupo Brasileiro De Mieloma Multiplo (GBRAM). <i>Blood</i> , 2021, 138, 4104-4104.	0.6	0
8	Progression Free Survival (PFS) Analysis of Daratumumab (Dara), Cyclophosphamide, Thalidomide and Dexamethasone: A Quadruplet Intensified Treatment for Transplant Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients. <i>Blood</i> , 2021, 138, 3943-3943.	0.6	0
9	Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation. <i>Hematology, Transfusion and Cell Therapy</i> , 2020, 42, 118-124.	0.1	2
10	Managing patients with multiple myeloma during the COVID-19 pandemic: recommendations from an expert panel " ABHH monoclonal gammopathies committee. <i>Hematology, Transfusion and Cell Therapy</i> , 2020, 42, 200-205.	0.1	10
11	First Description of Upfront Target Therapy Treating AML and Bcll Presented Simultaneously As First Line. <i>Blood</i> , 2020, 136, 25-26.	0.6	0
12	Immune Profiling Evaluation of Newly Diagnose Multiple Myeloma (NDMM) Transplant Eligible (TE) Patients Treated with Daratumumab, Cyclophosphamide, Thalidomide and Dexamethasone. Preliminary Results. <i>Blood</i> , 2020, 136, 3-4.	0.6	0
13	Preliminary Results of Daratumumab, Cyclophosphamide, Thalidomide and Dexamethasone: A Quadruplet Intensified Treatment for Newly Diagnosed Multiple Myeloma (NDMM) Transplant Eligible (TE) Patients. <i>Blood</i> , 2020, 136, 17-18.	0.6	0
14	Brazilian Real-World Multiple Myeloma (MM) Electronic Platform Register Project. <i>Blood</i> , 2020, 136, 4-4.	0.6	0
15	Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 cases. <i>Leukemia and Lymphoma</i> , 2019, 60, 471-476.	0.6	13
16	Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 118-123.	0.6	23
17	Survival differences in multiple myeloma in Latin America and Asia: a comparison involving 3664 patients from regional registries. <i>Annals of Hematology</i> , 2019, 98, 941-949.	0.8	9
18	New proteasome inhibitors in the treatment of multiple myeloma. <i>Hematology, Transfusion and Cell Therapy</i> , 2019, 41, 76-83.	0.1	25

#	ARTICLE	IF	CITATIONS
19	The impact of lactate dehydrogenase (LDH) in association with the International Staging System (ISS) on patients with multiple myeloma.. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e93.	0.2	1
20	Preliminary results of Daratumumab, cyclophosphamide, thalidomide and dexamethasone- A quadruplet intensified treatment to newly diagnosed multiple myeloma transplant eligible patients. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e145-e146.	0.2	0
21	Results of the Daratumumab Monotherapy Early Access Treatment Protocol (EAP) in Patients from Brazil With Relapsed or Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e246-e247.	0.2	0
22	Analysis of Availability and Access of Anti-myeloma Drugs and Impact on the Management of Multiple Myeloma in Latin American Countries. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e43-e50.	0.2	13
23	Multiple myeloma and central nervous system involvement: experience of a Brazilian center. Hematology, Transfusion and Cell Therapy, 2018, 40, 30-36.	0.1	15
24	Outcomes of Fresh Peripheral Stem Cell Transplants (PSCT) compared to Cryopreserved PSCT for the Treatment of Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S309-S310.	0.2	0
25	IgM myeloma: A multicenter retrospective study of 134 patients. American Journal of Hematology, 2017, 92, 746-751.	2.0	45
26	Primary Plasma Cell Leukemia: Epidemiologic and Clinical Profile from Patients Treated in a Brazilian Single Hematology and BMT Center. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S338-S339.	0.2	0
27	Identification of Amyloid Component in Bone Marrow Biopsy of Patients in the Diagnosis of Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S339-S340.	0.2	0
28	Analysis of the Availability of Anti-Myeloma Drugs and Impact on the Current Management of Myeloma in Latin American Countries. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, e15-e16.	0.2	0
29	Similar survival outcomes in patients with biclonal versus monoclonal myeloma: a multi-institutional matched case-control study. Annals of Hematology, 2017, 96, 1693-1698.	0.8	7
30	For survival, the emergence of oligoclonal bands after multiple myeloma treatment is less important than achieving complete remission. Revista Brasileira De Hematologia E Hemoterapia, 2017, 39, 331-336.	0.7	4
31	Observational study of multiple myeloma in Latin America. Annals of Hematology, 2017, 96, 65-72.	0.8	29
32	Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice. American Journal of Hematology, 2016, 91, 575-580.	2.0	83
33	Bilateral breast plasmacytoma: a clinical case report. Revista Brasileira De Hematologia E Hemoterapia, 2016, 38, 166-169.	0.7	9
34	Is it feasible to use granulocyte-colony stimulating factor alone to mobilize progenitor cells in multiple myeloma patients induced with a cyclophosphamide, thalidomide and dexamethasone regimen?. Revista Brasileira De Hematologia E Hemoterapia, 2016, 38, 302-309.	0.7	3
35	Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients. Leukemia and Lymphoma, 2016, 57, 2071-2076.	0.6	30
36	IgM Myeloma: A Multicenter Retrospective Study of 159 Patients. Blood, 2016, 128, 3276-3276.	0.6	0

#	ARTICLE	IF	CITATIONS
37	Multiple Myeloma: A Rare Case in an 8-Year-Old Child. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e31-e33.	0.2	9
38	Prevalence of Oligoclonal Bands in Multiple Myeloma Patients Who Achieved Better Results Than Very Good Partial Response after Treatment with Standard or High Doses Chemotherapy-Final Analysis. <i>Blood</i> , 2015, 126, 4210-4210.	0.6	0
39	Outcomes of autologous transplantation for multiple myeloma according to different induction regimens. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2014, 36, 19-24.	0.7	9
40	Comparison of Kappa & Lambda FreeLite to Total Kappa & Lambda Immunoassays for the Detection of Monoclonal Gammopathies, Both As Standalone Tests and Alongside Serum Protein Electrophoresis. <i>Blood</i> , 2014, 124, 5705-5705.	0.6	1
41	Venous Thromboembolism Prophylaxis with Aspirin for Multiple Myeloma Patients Receiving Thalidomide Combination As First-Line Treatment. <i>Blood</i> , 2014, 124, 5764-5764.	0.6	0
42	Guidelines on the diagnosis and management of multiple myeloma treatment: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular Project guidelines: Associação Médica Brasileira - 2012. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2013, 35, 201-17.	0.7	12
43	Dasatinib as a Bone-Modifying Agent: Anabolic and Anti-Resorptive Effects. <i>PLoS ONE</i> , 2012, 7, e34914.	1.1	61
44	Transcriptomic rationale for the synergy observed with dasatinib + bortezomib + dexamethasone in multiple myeloma. <i>Annals of Hematology</i> , 2012, 91, 257-269.	0.8	7
45	Hepatosplenic T-cell lymphoma associated to thiopurine in Ulcerative Colitis patient from Brazil: A case report. <i>Inflammatory Bowel Diseases</i> , 2011, 17, S52.	0.9	0
46	A Phase III Study Comparing Thalidomide/Cyclophosphamide/ Dexamethasone Vs Thalidomide/Dexamethasone Vs Thalidomide/Melphalan/Prednisone In De Novo Multiple Myeloma Patients Not Eligible for ASCT. <i>Blood</i> , 2011, 118, 5117-5117.	0.6	1
47	Evaluation of Angiogenesis and the CD57+ Lymphocytic Population on Bone Marrow Biopsies (BM) in Multiple Myeloma Patients Treated with Thalidomide (Thal). <i>Blood</i> , 2011, 118, 5095-5095.	0.6	0
48	In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. <i>Haematologica</i> , 2010, 95, 794-803.	1.7	144
49	Dasatinib Promotes Osteoprogenitor Differentiation and Inhibition of Osteoclastogenesis: Rationale for Treatment of Myeloma Bone Disease. <i>Blood</i> , 2009, 114, 3834-3834.	0.6	0